GlobeNewsWire
13 Jan 2026, 14:00 UTC · 42w ago
Verdict
Headline takes no side. We score IMDX +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
A joint AST and ASHI working group published a position paper concluding that high-quality, standardized decentralized dd-cfDNA testing is essential for real-world evidence-generating multicenter studies.
More positive than 98% of claims this week
iMDx CEO stated the working group's call for access to test kits is a strong indicator of pent-up industry demand for the decentralized testing model the company is building.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 85% of claims this week
iMDx expects that enabling decentralized testing will deliver new value in a roughly $1 billion-plus addressable market for kitted transplant rejection testing.
More positive than 75% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company's business strategy and flagship products are directly validated by a professional working group's call for decentralized transplant monitoring.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
15h ago
−62.7%
Price is moving against the score
$2.65 vs $7.11 close before publication (Jan 12) · not market-adjusted
IMDX chart →
